《半日速報》恆指半日收報27,980點 跌163點; 恆生科技指數半日收報7,607點 跌104點 藥明生物跌逾12% 東嶽集團、中國利郎創新高
恆指半日收27,980點,跌163點或0.6%。恆生科技指數報7,607點,跌104點或1.4%。國指跌41點或0.4%,報10,232點。
活躍重磅股表現:
平安(02318.HK) 收74.95元,上升1.6%;
港交所(00388.HK) 收462元,上升1.4%;
建行(00939.HK) 收6.16元,上升0.7%;
騰訊(00700.HK) 收556.5元,上升0.5%;
美團(03690.HK) 收285.8元,下跌0.4%;
阿裏巴巴(09988.HK) 收205.4元,下跌0.3%;
異動恆指及國指成份股:
藥明生物(02269.HK) 收120.6元,下跌12.6%;
阿裏健康(00241.HK) 收15.24元,下跌5.9%;
石藥(01093.HK) 收9.75元,下跌5.7%;
太保(02601.HK) 收25元,上升4.6%;
海底撈(06862.HK) 收42.75元,上升4.5%;
舜宇(02382.HK) 收233.4元,下跌3.8%;
中生製藥(01177.HK) 收7.06元,下跌3.7%;
瑞聲(02018.HK) 收55.7元,下跌3%;
異動綜合中小型股:
泰格醫藥(03347.HK) 收158.6元,下跌10.5%;
復星醫藥(02196.HK) 收55.9元,下跌10.3%;
東嶽集團(00189.HK) 收9.01元,上升10.3%,創新高;
金斯瑞生物科技(01548.HK) 收32元,下跌10.1%;
中國利郎(01234.HK) 收6.49元,上升4.8%,創新高;
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.